Arbutus Q2 FY26 net loss widens to $5.1 million; revenue drops 90.56% to $1.01 million
ABUS•R&D spending declines on cost cuts
R&D expense fell 47.27% to $2.9 million, on workforce reductions, ending in-house research, and lower clinical trial costs.
Patent enforcement actions continue
The company also filed international patent enforcement suits against Pfizer and BioNTech.
Cash position and capital return plans
Cash, cash equivalents and marketable securities totaled $92.6 million at June 30, 2026; the company also received $178.4 million in July from the Moderna settlement.
Arbutus plans to repurchase up to about $230 million of shares starting in Q3.
Q2 results weaken as revenue falls sharply
Arbutus Biopharma posted a Q2 net loss of $5.1 million, swinging from net income of $2.5 million a year earlier.
Revenue slid 90.56% to $1.01 million, due to recognition of deferred revenue in Q2 2025 after the Qilu partnership ended.
